20.1 Site Qualification and Investigator Capacity

Site Qualification and Investigator Capacity

In clinical research, the Clinical Research Associate (CRA) serves as the sponsor's investigative eyes and ears during the site selection process. While commercial sponsor business development teams or CRO feasibility departments initiate site identification through electronic surveys, the CRA validates these representations in the physical clinic.

A misjudged site selection—such as selecting a renowned academic investigator who lacks time to oversee study staff, or a private clinic with an inadequate patient referral network—leads directly to delayed study milestones, poor data quality, protocol non-compliance, and costly rescue site activations.

Feasibility Questionnaires vs. Pre-Study Visits (PSV/SQV)

Site evaluation follows a progressive funnel that transitions from broad statistical surveying to granular, in-person operational verification.

The Site Feasibility Questionnaire (SFQ)

Before any proprietary protocol information is shared, the investigative site and sponsor execute a mutual Confidential Disclosure Agreement (CDA). Once protected, the site receives a protocol synopsis and a structured Site Feasibility Questionnaire (SFQ). The SFQ collects self-reported institutional metrics, including:

• Estimated monthly patient volume matching broad inclusion/exclusion criteria.
• Active competing clinical trials in the same indication.
• Standard-of-care diagnostics and hospital department capabilities.
• Institutional Review Board (IRB) or Independent Ethics Committee (IEC) review timelines and reliance policies.
• Site staff credentials and dedicated research staffing levels.

The Pre-Study Visit (PSV) / Site Qualification Visit (SQV)

While the SFQ provides a preliminary quantitative baseline, self-reported metrics are notoriously susceptible to optimistic bias. Recruitment estimates may be optimistic and need an evidence-based rationale. The Pre-Study Visit (PSV)—also termed the Site Qualification Visit (SQV)—represents the formal audit step where the CRA verifies the physical reality of the site's written responses.

Critical Evaluation Domains During the PSV/SQV

During the PSV, the CRA executes a systematic evaluation of five core operational pillars required under ICH E6(R3):

A. Investigator Qualifications, Specialty & Verifiable Time

Under ICH E6(R3), the investigator must be qualified by education, training, and experience, and must have adequate time to properly supervise the trial. The CRA must evaluate:

• Medical Specialty & Board Certification: The PI's therapeutic background must directly match the study indication (e.g., a board-certified medical oncologist for a Phase III solid-tumor trial, or an experienced neurologist for an Alzheimer's disease investigation).
• GCP Fluency & Trial Experience: Prior clinical trial experience as a PI or Sub-investigator, familiarity with electronic data capture (EDC), and verifiable GCP training certificates (maintained under applicable training requirements).
• The "Overextended PI" Syndrome: A prominent clinical researcher or department chair may attract numerous study awards but possess zero bandwidth for actual day-to-day supervision. The CRA must explicitly calculate the PI's current commitments: hospital inpatient rounds, surgical schedules, private clinic hours, academic teaching duties, and existing active research trials. If a PI manages 15 active clinical trials while maintaining a full surgical schedule, human subject oversight is severely jeopardized.
• Scientific Engagement: Does the PI demonstrate genuine enthusiasm for the protocol's scientific objectives, or is the trial viewed merely as a secondary revenue stream?

B. Site Staff Resources & Workload Balancing

Trial execution depends heavily on the operational competence and stability of the site's research infrastructure:

• Clinical Research Coordinator (CRC) Bandwidth: The lead study coordinator is the central administrative engine of the trial. The CRA must determine how many active studies each coordinator manages. Assess coordinator capacity from the actual workload, complexity, staffing and backup, without a universal study-count ceiling.
• Dedicated Support Staff: Presence of dedicated research nurses, phlebotomists, certified unblinded study pharmacists, and clinical data entry personnel.
• Staff Turnover & Retention: High coordinator turnover is an immediate operational hazard, causing lost institutional knowledge, missing documentation, and training gaps.
• Back-Up Coverage: Documented availability of cross-trained backup coordinators and sub-investigators who can maintain study continuity during planned leaves or unexpected departures.

Official sources

Checked October 18, 2026: ICH E6(R3), Principles and Annex 1, ICH E8(R1).